Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines. 2020

Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, Athens 15771, Greece.

The design and synthesis of a number of new imidazo[4,5-b]pyridines is described. The heterocyclic scaffold possesses 6-chloro- or 5,6-dichloro-substitution and bears various 2-alkylamino-methyl or ethyl groups. The corresponding N1 and N3-tosylates are also presented. The anti-HBV activity of the compounds was evaluated in HBV infectious system at the level of HBV rcDNA secretion and CC50, EC50 and selectivity index values were determined. The tosylates showed low antiviral potency and relatively high cytotoxicity, on the contrary, a number of 2,5 and/or-6-substituted imidazopyridines, mainly those belonging to the 6-chloroimidazo[4,5-b]pyridine series, were endowed with a very interesting profile and were further investigated. The most promising among them, along with the reduction of the secreted HBV rcDNA, also caused a reduction in HBV cccDNA and pgRNA levels, with a concomitant accumulation of the intracellular encapsidated rcDNA. Surprisingly, the most active 2-diethylaminoethyl-substituted derivative (21d), was highly competitive to interferon.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
December 2022, Molecules (Basel, Switzerland),
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
October 1987, Journal of medicinal chemistry,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
October 2014, ACS combinatorial science,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
December 1998, Anti-cancer drug design,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
May 2013, Organic & biomolecular chemistry,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
March 1992, Farmaco (Societa chimica italiana : 1989),
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
September 1978, Journal of medicinal chemistry,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
June 2012, ChemMedChem,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
November 1976, The Journal of organic chemistry,
Maria Gerasi, and Efseveia Frakolaki, and Georgios Papadakis, and Anna Chalari, and Nikolaos Lougiakis, and Panagiotis Marakos, and Nicole Pouli, and Niki Vassilaki
April 2012, Organic letters,
Copied contents to your clipboard!